Spongouridine

Spongouridine

Contact : Mr.Thyen------------------------------- Email us at zhangyinglong@ycphar.com Whatsapp : +86 180 3817 6818

Product Details


Spongouridine


Contact : Mr.Thyen

Email us at zhangyinglong@ycphar.com

Whatsapp : +86 180 3817 6818


CAS: 3083-77-0

MF: C9H12N2O6

MW: 244.2

EINECS: 221-386-9

Synonyms: 1-beta-d-arabinofuranosyl-uraci ;1-[3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione;1-beta-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione;Spongouridine;Uridine;1--D-Arabinofuranosyl-2,4(1H,3H)-pyrimidinedione;NSC 68928;1-(β-D-Arabinopyranosyl)uracil

img30142.jpg

Properties

Melting point:220-222°C

storage temp. 2-8°C

Form: Powder

Color: White to Off-white

 

Clinical indication

Vidarabine is an antiviral, active against herpes viruses, poxviruses, rhabdoviruses, hepadnaviruses and some RNA tumour viruses. A 3% ophthalmic ointment Vira-A is used in the treatment of acute keratoconjunctivitis and recurrent superficial keratitis caused by HSV-1 and HSV-2. Vidarabine is also used to treat herpes zoster in AIDS patients, reducing lesions formation and the duration of viral shedding.


Many of the previous uses of vidarabine have been superseded by acyclovir, due to the hospitalisation required for intra venous dosing, and acyclovir has a higher selectivity, lower inhibitory concentration and higher potency. Toxic side effects are rare, but have been reported with high concentrations of vidarabine, such as nausea, vomiting, leukopenia and thrombocytopenia in patients receiving high intravenous doses daily.


Arabinoside is also used to treat herpes zoster in AIDS patients, reducing the incidence of disease and virus shedding time. Many of the previous use of arabinoside has been substituted for acyclovir, due to intravenous administration of the required hospitalization, and acyclovir has a high selectivity, low bacteriostatic concentration and higher potency. The side effects are rare, but there are reports of high concentrations of arabinoside, such as nausea, vomiting, in patients receiving high doses of intravenous daily leukocyte and thrombocytopenia.

Inquiry